Meiji Seika Pharma Expands Presence in Asia with New Subsidiary in Taiwan

Tokyo, Japan – Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, President: Daikichiro Kobayashi) proudly announces the establishment of its new subsidiary, Taiwan Meiji Pharma Co., Ltd. Set to be based in Taipei City, this strategic venture underscores Meiji Seika Pharma’s commitment to enhancing healthcare solutions across Asia. The subsidiary is scheduled to begin operations in February 2025 under the leadership of Chairman Kenshi Murase.

Guided by the ambitious "Meiji Group 2026 Vision," which envisions leadership in infectious disease treatment across Asia, this initiative positions Meiji Seika Pharma in Taiwan—the fifth-largest pharmaceutical market in the region. The company aims to build a robust foundation for growth, focusing on delivering innovative therapies and expanding its product portfolio.

One of the flagship products planned for launch is "REZUROCK" (generic name: belumosudil mesylate), a selective ROCK2 inhibitor for treating chronic graft-versus-host disease (Chronic GVHD). This life-altering condition often arises after hematopoietic stem cell transplantation for leukemia treatment. Currently under review by the Taiwan Food and Drug Administration (TFDA), REZUROCK reflects the company's dedication to addressing critical unmet medical needs.

Beyond this, Taiwan Meiji Pharma is exploring opportunities to introduce additional vital therapies, including antibiotics and vaccines, further strengthening its role as a trusted partner in Taiwan’s healthcare landscape.

Company at a Glance

Name: Taiwan Meiji Pharma Co., Ltd.

Headquarters: 14F, No. 51 Section 2, Keelung Rd., Xinyi District, Taipei City, 110502, Taiwan

Chairman: Kenshi Murase

Focus: Pharmaceutical sales and related activities

Capital: 30 million New Taiwan Dollars

Establishment Date: December 18, 2024

Ownership: 100% subsidiary of Meiji Seika Pharma Co., Ltd.

By establishing this subsidiary, Meiji Seika Pharma seeks to ensure a stable supply of its high-quality pharmaceutical products, delivering tangible benefits to patients in Taiwan and supporting the nation’s healthcare objectives.